Tag: Decongestant alternatives

In September 2023, a U.S. Food and Drug Administration (FDA) advisory committee unanimously concluded that oral phenylephrine, a key ingredient in hundreds of over-the-counter cold medicines, is ineffective at relieving nasal congestion [1.3.1, 1.3.3]. This article explains what nasal decongestant is being discontinued as a result and what consumers should use instead.

Tavist-D, a combination medication containing clemastine and phenylpropanolamine, was voluntarily withdrawn from the market following a U.S. Food and Drug Administration (FDA) recommendation due to an increased risk of hemorrhagic stroke associated with one of its active ingredients. This article explains what is Tavist D used for and provides guidance on safer alternatives for managing allergy and cold symptoms.